Sintilimab+Anlotinib+Pemetrexed+Cisplatin

Phase 2Small molecule

CCancer Institute and Hospital, Chinese Academy of Medical Sciences

Sintilimab+Anlotinib+Pemetrexed+Cisplatin is one of 10 small molecule programs targeting Malignant Pleural Mesothelioma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Malignant Pleural MesotheliomaRecruiting

Malignant Pleural MesotheliomaPhase 2

Recruiting

Competition

Competitive Landscape

12 competitors in Malignant Pleural Mesothelioma

#DrugCompanyPhaseTrials

Keytruda

Merck & Co.

Phase 3

8 2

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 3

21 3

Opdivo

Bristol-Myers Squibb

Phase 3

4 4

Photofrin

PPinnacle Biologics Inc.

Alimta

14 6

Tecentriq

Roche

Phase 3

3 7

Yervoy

Bristol-Myers Squibb

Phase 3

1 8

Lenvima

Eisai

Phase 2

2 9

OT-101

OOncotelic Inc.

Phase 2

1 10

Sintilimab+Anlotinib+Pemetrexed+Cisplatin

CCancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 2Recruiting

Malignant Pleural Mesothelioma

NCT05188859

Clinical

Trials by Indication[1]

Malignant Pleural Mesothelioma1 trial

First Line Sintilimab Combined With Anlotinib and Platinum Doublet Chemotherapy in Malignant Pleural Mesothelioma

Recruiting·—·Phase 2·NCT05188859·29 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Sintilimab+Anlotinib+Pemetrexed+Cisplatin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Sintilimab+Anlotinib+Pemetrexed+Cisplatin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Sintilimab+Anlotinib+Pemetrexed+Cisplatin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Cancer Institute and Hospital, Chinese Academy of Medical Sciences company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: CCancer Institute and Hospital, Chinese Academy of Medical Sciences

Sintilimab+Anlotinib+Pemetrexed+Cisplatin

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Trials by Indication[1]

Malignant Pleural Mesothelioma1 trial

References

Drug Info

Quick Facts

Related News